

LINC01093 promotes proliferation and invasion of non-small cell lung cancer cells via targeting akt signaling pathway

Z.-X. WANG¹, Z.-N. XU¹, H.-B. SUN¹, Y. WANG¹, Z.-F. HAN¹, Y. YIN², X.-L. HAN³, Y.-Y. YIN¹, L. XU¹

¹Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China

²Department of Emergency, Jilin City People's Hospital, Jilin, China

³Department of Radiotherapy, Changchun Tumor Hospital, Changchun, China

Zhenxing Wang and Zhenan Xu contributed equally to the work.

Abstract. – OBJECTIVE: To explore the expression of LINC01093, a long non-coding ribonucleic acid (lncRNA) in non-small cell lung cancer (NSCLC) tissues, and cells and its regulatory role in NSCLC cell proliferation and invasion.

PATIENTS AND METHODS: The expression of LINC01093 in NSCLC tissues and cells was detected via quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) experiment. The specific sequences interfering with LINC01093 were designed and transiently transfected into A549 and SPCA-1 cells using Lipofectamine™ 2000, and 48 later the transfection efficiency was detected. Further, the impacts of small interfering (si) LINC01093 on NSCLC cell proliferation were observed in methyl thiazolyl tetrazolium (MTT) and colony forming assays, the influence of LINC01093 on cell cycle distribution of NSCLC cells was determined through flow cytometry, and the changes in the invasion and migration abilities of NSCLC cells were evaluated via well assay and interfering in the expression of LINC01093. Finally, the expression changes of the molecular markers in the protein kinase B (Akt) signaling pathway in the downstream of LINC01093 were detected via Western blotting.

RESULTS: According to the results of qRT-PCR, the relative expression level of LINC01093 was up-regulated in NSCLC tissues and cells. Interfering with the expression of LINC01093, the results of MTT and colony forming assays revealed that the proliferation ability of NSCLC cells was weakened, according to the findings in flow cytometry, the cells were arrested in G0/G1 phase. The transwell assay results manifested that the cell migration and invasion abilities were weakened, and the results of the Western blotting suggested the changes in the expressions of molecular markers in the Akt signaling pathway.

CONCLUSIONS: The expression of LINC01093 is up-regulated in NSCLC tissues and cells, and facilitates the proliferation, invasion, and metastasis of NSCLC cells via the Akt signaling pathway.

Key words:

Non-small cell lung cancer, LINC01093, Proliferation, Invasion and migration, Akt signaling pathway.

Introduction

In recent years, the incidence and mortality rates of lung cancer have been increasing, and it is one of the cancers with the highest incidence and mortality rates worldwide¹. Non-small cell lung cancer (NSCLC) represents 75-80% of the total lung cancer cases². For the lack of typical clinical manifestations, it is relatively difficult to perform the early-stage screening for NSCLC, and most patients stayed at an advanced stage when diagnosed for the first time. Additionally, poor prognosis is also a grave issue facing in the current treatments³. Therefore, seeking effective markers for the early diagnosis and prognosis is of great scientific significance and clinical value.

Gene therapy for tumors is gradually becoming a research hotspot now, and the search for NSCLC-associated oncogenes and tumor suppressor genes provides new research directions for the diagnosis and treatment of NSCLC as well⁴. Long non-coding ribonucleic acids (lncRNAs) measuring more than 200 nt in length regulate the proliferation, apoptosis, metastasis, and other biological functions of cancer cells, playing a role

as “tumor suppressor gene” or “oncogene”⁵. Latest researches have found that several lncRNAs, such as lncRNA MALAT1⁶, lncRNA5 [growth arrest-specific gene 5 (GAS5)]⁷ and lncRNA HOX antisense intergenic RNA (HOTAIR)⁸, are aberrantly expressed in NSCLC and participate in its pathological occurrence and development. New lncRNAs related to NSCLC should still be investigated through further studies.

LINC01093 is located on chromosome 4q35.1 and 1529 bp in full length. According to a literature report, the expression of LINC01093 is down-regulated in hepatocellular carcinoma, and lowly-expressed LINC01093 can be taken as an independent predictor for the prognosis of hepatocellular carcinoma patients⁹. He et al¹⁰ found that LINC01093 is lowly expressed in hepatocellular carcinoma and related to the TNM stage in patients with this disease. In addition, they discovered that the molecular mechanism experiment results have established that LINC01093 binds to IGF2BP1 to degrade GLI1 messenger RNAs (mRNAs) and repress the proliferation and other biological features in hepatocellular carcinoma. However, the expression and biological function of LINC01093 in NSCLC tissues and cells has not yet been reported.

In this study, it was discovered for the first time that the expression of LINC01093 was upregulated in NSCLC tissues and cells, and the highly expressed LINC01093 accelerated proliferation, invasion, and metastasis of NSCLC cells via the protein kinase B (PKB) signaling pathway. The above findings offer a new potential molecular targets to reverse the regulation of the malignant phenotype of NSCLC.

Patients and Methods

Tissue Specimens

A total of 56 NSCLC patients undergoing surgery in the Department of Chest Surgery in China-Japan Friendship Hospital of Jilin University from 2011 to 2012 were selected as subjects, and their cancerous tissues and para-cancerous tissues at 2 cm away from the tumor were taken. Postoperatively, these patients were definitely diagnosed via histological examination. Before the operation, all the patients aged 31-75 years old did not undergo radiotherapy, chemotherapy, or immunotherapy or take targeted therapeutic drugs. This study was approved by the Ethics Committee of our hospital, and the enrolled patients signed the

written informed consent. The cancerous tissues and para-cancerous normal tissues collected were cryopreserved at -180°C.

Cell Culture

Human bronchial epithelial cells (16HBE) and NSCLC cell lines (adenocarcinoma: A549 and SPC-A1, squamous carcinoma: H1975) (Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences) were cultured with the Dulbecco's Modified Eagle's Medium (DMEM)/RPMI 1640 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA) in a thermostatic incubator at 37°C with 5% CO₂.

Quantitative Real-time Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

16HBE cells, NSCLC cells, and cancerous or para-cancerous tissues were lysed with an appropriate amount of TRIzol (Invitrogen, Carlsbad, CA, USA) and added with chloroform for extraction and vortexing. After high-speed centrifugation, the isopropanol was added to accelerate precipitation, and the precipitates were washed using anhydrous alcohol, centrifuged, collected, and dissolved with diethylpyrocarbonate-treated water. Then, the concentration of RNAs was determined. The total RNAs (1 µg) were reversely transcribed into complementary deoxyribonucleic acids (cDNAs). The qRT-PCR program was set as follows: pre-denaturation at 95°C for 30 s, denaturation at 95°C for 5 s, annealing and extension at 60°C for 31 s, for 40 cycles and performed, and then the data were analyzed using the 7300 system SDS software. Finally, the relative quantification (RQ) value was calculated based on cycle threshold (Ct) using the formula $RQ=2^{-\Delta\Delta C_t}$ and reflected the relative expression level of the genes detected.

Primers and Small Interfering (si)RNAs

The primer sequences were: linc 01093 Forward 5'-AGTTCTTCTAGATTGCGTT-3', linc 01093 Reverse 5'-ATTGACATGGGATGCCCTT-3', glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Forward 5'-CCCAC TTGAAGGGTG-GAGCCAA-3', GAPDH Reverse 5'-TGGCATG-GACTGTGGTCA TGA-3', si-linc 01093 #1, sense 5'-CGACAGUGCUIGUGAACUUTT-3', and antisense 5'-CCAUUCAGUACGAGAGUCCTT-3'; si-linc 01093 #2, sense 5'-ACUGACG CUGAC-

CAUGUGATT-3', and antisense 5'-ACUGGU-CAUCAGU AUCCATT-3'. si-line 01093 #3, sense 5'-CCAAGGCUGGAACUGAUATT-3', and antisense 5'-GC AACGAAUCCGGAUCG-CATT-3'. The primer and interfering sequences were designed and synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China).

Methyl Thiazolyl Tetrazolium (MTT) and Colony Forming Assays

MTT assay was performed according to the following specific steps: the NSCLC cells were transfected with si-LINC01093 and inoculated into a 96-well plate (3×10^3 cells/well), and each well of cells was incubated with 10 μ L of MTT solution in the incubator for 1 h. Subsequently, they were added with 100 μ L of formazan dissolving solution and continued to be incubated for 4 h. Finally, an ultraviolet spectrophotometer was used to determine the optical density (OD) at 570 nm. The colony forming assay was conducted as follows: after being transfected with si-LINC01093, the NSCLC cells were seeded into a 6-well plate (1.2×10^3 cells/well), and the medium was replaced every three days. After 14 d, with the medium removed, the cells were covered and fixed with 100% methanol for 15 min, stained with crystal violet for 15 min and washed using Phosphate-Buffered Saline (PBS) twice.

Flow Cytometry

Cell cycle distribution was detected according to the following procedure. Firstly, si-LINC01093 and si-NC were transiently transfected into NSCLC cells, and 6 h later the cells were inoculated into a 6-well plate and cultured for 48 h. Then, the cells were harvested, re-suspended in 75% ethanol, and fixed at 4°C overnight. Finally, the content of DNAs in cells was determined via flow cytometry and PI staining, and the percentage of cells in each time phase was calculated using the software.

Transwell Assay

The lower chamber of transwell was added with 500 μ L of medium containing 10% fetal bovine serum (a Millipore chamber pre-paved with Matrigel and a Millipore chamber without Matrigel for cell invasion and migration assays, respectively, Millipore, Billerica, MA, USA), and 2×10^5 cells (200 μ L) were added to the upper chamber and cultured in the incubator for 48 h. With the liquid in the upper chamber discarded, the chamber was taken out carefully, and

the cells which failed to penetrate through the chamber membrane were removed using the wet cotton swab. Then, the resulting cells were fixed in methanol for 2 min, stained with crystal violet for 5 min, and washed using PBS. Finally, the chamber membrane was cut and counted.

Western Blotting

The cells were collected from the experimental group and control group and added with protein lysis buffer, and the concentration of proteins was determined using the bicinchoninic acid (BCA) protein assay kit (Pierce and Warriner, USA). Then, 10% separation and staining gels were prepared, and appropriate loading volumes were calculated based on the above-mentioned protein concentration determined, 20 μ g of proteins were loaded and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA) by the wet transfer method at 80 V for 30 min and 120 V for 1 h, respectively. Subsequently, the membranes were incubated with the primary antibody of phosphorylated Akt (p-Akt), T-Akt, p21, and p53 (Immobilon, Carlsbad, CA, USA) at 4°C overnight, washed using Tris-Buffered Saline with Tween-20 (TBST), incubated with the secondary antibody at room temperature, rinsed with TBST and probed on the ChemiDoc XRS+ imaging system for development.

Statistical Analysis

In statistical processing, Statistical Product and Service Solutions (SPSS) 18.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. The *t*-test was used for analyzing the measurement data. The differences between the two groups were analyzed using the Student's *t*-test. The comparison between multiple groups was done using One-way ANOVA test followed by the post-hoc test (Least Significant Difference). $p < 0.05$ denoted that the difference was statistically significant.

Results

The Expression of LINC01093 Was Upregulated in NSCLC Tissues and Cells

The expression level of LINC01093 in the cancerous and para-cancerous tissues from 56 NSCLC patients was determined via qRT-PCR, and it was found that, compared with that in para-cancerous tissues, the expression level of LINC01093 was raised in NSCLC tissues (Figure 1A). Then,

the expression level of LINC01093 in NSCLC cells (A549, SPCA-1, and SK-MES-1) and human bronchial epithelial cells (16HBE) was measured via qRT-PCR, and the results revealed that the expression of LINC01093 was up-regulated in NSCLC cells (Figure 1B). Additionally, to explore the biological function of LINC01093 in NSCLC cells, A549 and SPCA-1 cells were taken as the model cells and transiently transfected with

the specific interfering sequences of LINC01093 (si-LINC01093) designed by the research group. 48 h after transfection, the interference efficiency was measured (Figures 1C, 1D).

Influence of LINC01093 on NSCLC Cell Proliferation

Firstly, A549 and SPCA-1 cells were transiently transfected with si-LINC01093 and si-NC, and




Figure 1. Expression of LINC01093. **A**, Expression level of LINC01093 in 56 pairs of NSCLC tissues and para-cancerous tissues was determined via qRT-PCR: compared with that in para-cancerous tissues, the expression of LINC01093 is up-regulated in 44 cases and down-regulated in 12 cases, with GAPDH as the internal reference. **B**, The relative expression level of LINC01093 in NSCLC cells and 16HBE cells measured via qRT-PCR. **C**, The transfection efficiency of the designed sequences interfering in LINC01093 detected via qRT-PCR. (** $p < 0.01$, and * $p < 0.05$).

then they were inoculated into a 96-well plate (3×10^3 cells/well). After inoculation, OD was measured at five observation time points 0, 24, 48, 72, and 96 h, and the growth curve was plotted. It was discovered that the interference in the expression of LINC01093 inhibited the prolifer-

ation of NSCLC cells (Figures 2A, 2B), which is consistent with the colony forming assay results (Figures 2C, 2D). Furthermore, the influence of LINC01093 on NSCLC cell cycle distribution was explored. Firstly, the cells in both the experimental group and control group were seeded into 6-well




Figure 2. Influence of LINC01093 on NSCLC cell proliferation. **A-B**, The impacts of si-LINC01093 on the proliferation ability of A549 and SPCA-1 cells detected via MTT assay. **C-D**, Impacts of si-LINC01093 on the proliferation ability of A549 and SPCA-1 cells detected via colony forming assay (magnification: 10 \times). **E-F**, Cell cycle distribution detected using flow cytometry after intervening in the expression of LINC01093 in A549 and SPCA-1 cells. (** $p < 0.01$, and * $p < 0.05$).

plates, separately and 48 h later, they were collected. Then, the cell cycle distribution was detected via flow cytometry, and the results showed that the knockdown of LINC01093 arrested NSCLC cells in G1/0 phase (Figures 2E, 2F).

Impact of LINC01093 on the Migration and Invasion of NSCLC Cells

Firstly, the cells in the experiment group and control group were inoculated into chambers,

separately, and cultured for 48 h. Then, the liquid in the upper chamber was discarded, and the resulting cells were fixed using methanol and stained with crystal violet. The results manifested that the intervention in the expression of LINC01093 weakened the migration and invasion abilities of NSCLC cells (Figures 3A, 3B). To verify the potential molecular mechanism by which LINC01093 exerts its biological functions, the changes in molecular markers




Figure 3. LINC01093 acts through the AKT signaling pathway. **A-B**, Changes in cell migration and invasion abilities detected via Transwell assay after interfering in the expression of LINC01093 in A549 and SPCA-1 cells (magnification: 40×). **C-D**, The changes in the expressions of the molecular markers in the AKT signaling pathway detected by Western blotting after interfering in the expression of LINC01093 in A549 and SPCA-1 cells.

Akt1 signaling pathway were detected via Western blotting in this study. It was discovered that, compared with those in the control group, the protein expressions of p-Akt, p21, and c-Myc in the cells were changed in the experiment group (Figures 3C, 3D).

Discussion

ncRNAs can fall into short strand ncRNAs (≤ 200 nt) and lncRNAs (>200 nt) according to the length. lncRNAs have previously been recognized as the “wastes” produced in the transcription, and we believed that they represented the low fidelity of RNA polymerases in such a process¹¹. Over the past years, lncRNAs have attracted extensive attention as oncogenes or tumor suppressor genes, and their dysfunction is closely correlated with the occurrence of multiple tumors, including NSCLC¹².

Shen et al¹³ followed 78 NSCLC patients for 5 years, and they found that the expression level of metastasis-associated to lung adenocarcinoma transcript 1 (MALAT1), which is the first lncRNA researched in the lung cancer, is closely related to the survival time of patients. They also discovered that the median survival time of patients is 52 and 60 months in MALAT1 high expression and low expression group, respectively. The above findings indicate that MALAT1 is associated with the prognosis of NSCLC patients and thus serves as an independent factor reflecting prognosis. High expression of MALAT1 predicts a poor prognosis in the patients. GAS6-Axl, a new lncRNA discovered by Han et al¹⁴, is located on the down-stream of GAS6 and acquired via antisense transcription. According to the findings of the research, compared with normal tissues adjacent to NSCLC tissues, the cancerous tissues show a decreased expression level of GAS6-Axl while its expression is negatively correlated with TNM stage. GAS6, the host gene of GAS6-Axl, can effectively promote the proliferation, migration, and infiltration of NSCLC cells. Further studies have found that GAS6-Axl is negatively correlated with GAS6 in NSCLC tissue cells, suggesting that GAS6-Axl may regulate the expression of GAS6 to participate in the occurrence and development of NSCLC. However, there have not yet been reports on the expression and biological function of LINC01093 in NSCLC tissues and cells.

The present research discovered for the first time that the expression of LINC01093 was up-regulated in NSCLC tissues and cells, and highly expressed LINC01093 could promote proliferation, migration, and invasion. Since the relationships of LINC01093 with the clinicopathological features of NSCLC patients were not further analyzed in this study, these information of such patients will be considered to probe the correlations between LINC01093 expression with the stage and prognosis of these patients in subsequent researches. In the present study, the potential mechanism of action of LINC01093 was preliminarily explored based on the above experimental results.

The family of serine/threonine protein kinase, has 3 major members, namely Akt1, 2 and 3, and large amount of literature¹⁵ have revealed that Akt is abnormally activated in such malignancies as liver cancer, breast cancer, and thyroid cancer. Since Akt facilitates the growth and proliferation of tumor cells, Akt has been regarded as an important target for researching and developing anti-tumor drugs, for instance, some broad-spectrum Akt inhibitors, like AZD5363, have been subjected to clinical trials, as the drug has been used in breast and gastric cancers^{16,17}. Similarly, in many studies^{18,19}, the Akt family has been found to bear close relationships with the proliferation and metastasis of NSCLC cells, while the interaction between LINC01093 and the Akt signaling pathway in NSCLC has not yet been reported. The present study discovered that after interfering in the expression of LINC01093, the expression of T-Akt was not changed, but on the other hand, that of p-Akt did.

Conclusions

Altogether, the expression of LINC01093 is up-regulated in NSCLC tissues and cells, and it facilitates the proliferation, invasion, and metastasis of NSCLC cells via the Akt signaling pathway.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

This work was supported by the Jilin Science and Technology Development Project (20180201046YY).

References

- 1) SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; 68: 7-30.
- 2) LIU L, ZHOU XY, ZHANG JQ, WANG GG, HE J, CHEN YY, HUANG C, LI L, LI SQ. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. *Eur Rev Med Pharmacol Sci* 2018; 22: 8722-8730.
- 3) ZHANG Q, NONG J, WANG J, YAN Z, YI L, GAO X, LIU Z, ZHANG H, ZHANG S. Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small-cell lung cancer. *Oncol Lett* 2019; 17: 3799-3807.
- 4) BARR JA, HAYES KE, BROWNMILLER T, HAROLD AD, JAGANNATHAN R, LOCKMAN PR, KHAN S, MARTINEZ I. Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells. *Sci Rep* 2019; 9: 3662.
- 5) SPARBER P, FILATOVA A, KHANTEMIROVA M, SKOBLIOV M. The role of long non-coding RNAs in the pathogenesis of hereditary diseases. *BMC Med Genomics* 2019; 12: 42.
- 6) YANG Q, CHEN W, XU Y, LV X, ZHANG M, JIANG H. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. *Toxicol Appl Pharmacol* 2018; 363: 1-10.
- 7) CAO L, CHEN J, OU B, LIU C, ZOU Y, CHEN Y. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to docetaxel (DDP) through regulating miR-21/PTEN pathway. *Biomed Pharmacother* 2017; 93: 570-579.
- 8) YANG Y, JIANG C, YANG Y, GUO Y, LIU X, WANG C, ZOU J. Silencing of LncRNA-HOXA11 decreases drug resistance of non-small cell lung cancer cells by inactivating Akt pathway through decreasing the phosphorylation of GSK-3β. *Biomed Res Commun* 2017; 9: 100-104.
- 9) WANG Z, WU Q, WANG S, ZHAO Y, LIU Y. Identification of four potential lncRNAs for survival prediction of patients with hepatocellular carcinoma. *PeerJ* 2017; 5: e3573.
- 10) HE J, ZHANG Q, HU B, JIN F, LIU C, CHENG Z, DENG X, YANG C, RUAN H, YU C, ZHANG M, FANG J, GU J, LIU J, FAN J, QIN W, YANG XR, WANG H. A novel liver-specific long noncoding RNA LINC01093 accelerates HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. *Cancer Lett* 2019; 450: 98-109.
- 11) RICCIUTI B, MENCARONI C, PAGLIALUNGA L, PACELO NO L, CHIARI R, METRO G. Long noncoding RNAs: insights into non-small cell lung cancer biology, diagnosis and therapy. *Med Oncol* 2015; 33: 18.
- 12) CHEN J, WANG R, ZHANG K, CHEN Y. Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. *J Oncol Med* 2014; 18: 2425-2436.
- 13) SHEN L, CHEN L, WANG Y, WANG X, XIA H, ZHUANG Z. Noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. *J Neurooncol* 2017; 131: 101-108.
- 14) HAN L, KONG Y, YIN DD, LIU FB, YANG P, DE W, SHU YQ. Low expression of long non-coding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. *Int J Oncol* 2013; 36: 694.
- 15) MUNDI PS, SACHDEV RNS, COURT C, KALINSKY K. AKT in cancer: new molecular insights and advances in drug development. *Br J Clin Pharmacol* 2016; 82: 943-956.
- 16) RIBAS R, PANCHANG S, GUEST SK, MARANGONI E, GAO Q, THULEAU A, SINGHALA N, POLANSKA UM, CAMPBELL H, PANI A, LICCARINO J, JOHNSTON S, DAVIES BR, DOWSETT M, MARTIN LA. The AKT antagonist AZD5363 influences PI3K receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. *Mol Cancer Ther* 2015; 14: 2035-2048.
- 17) VAN DE VLIET A, BANERJI U, SCHELLENS J, KREBS MG, JIMENEZ B, VAN BRUMMELEN E, BAILEY C, CASSON E, CRIPPS D, CULLBERG M, EVANS S, FOXLEY A, LINDEMANN J, RUGMAN P, TAYLOR N, TURNER G, YATES J, LAWRENCE P. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. *Cancer Chemother Pharmacol* 2018; 81: 873-883.
- 18) RAO G, PIEROBON M, KIM IK, HSU WH, DENG J, MOON YW, PETRICOIN EF, ZHANG YW, WANG Y, GIACCONE G. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. *Sci Rep* 2017; 7: 7066.
- 19) LIU X, JIANG Q, LIU H, LUO S. Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells. *Biol Res* 2019; 52: 7.